ArticleBMC complementary medicine and therapies2025
Comparative antibacterial activity of clove extract against Pseudomonas aeruginosa.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Phytochemical Profile and Bioactive Potential ofCurrent issues in molecular biology · 2026Article
- Tibetan Medicine Liuwei Dingxiang Pills Decoction InhibitsInfection and drug resistance · 2026Article
- Inhibitory Effects and Mechanisms of Athyrium multidentatum Against Staphylococcus aureus and Bacillus cereus.Chemistry & biodiversity · 2026Article
- Medicinal plants: bioactive compounds, biological activities, combating multidrug-resistant microorganisms, and human health benefits - a comprehensive review.Frontiers in immunology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen belonging to the γ-proteobacteria family, known to cause pneumonia linked with ventilator use and nosocomial infections. With the increasing prevalence of antibiotic-resistant bacteria, there is a pressing need to identify alternatives to conventional antibiotics. Plant-derived substances (PDSs) offer potential not only as antibacterial agents but also as modulators of antibiotic resistance. In this study, diffusion assay using disc agar, and the minimum inhibitory concentration (MIC) assay of each imipenem, amoxicillin-clavulanic acid, and clove extract was determined. The clove extract was analyzed via the UHPLC/MS, and the checkerboard assay was employed to evaluate the potential synergistic effects of combining clove extract with both antibiotics. The combination of clove extract to each antibiotic led to a significant reduction in their respective MICs. Moreover, each antibiotic exhibited synergistic effects on the fractional inhibitory concentration value (FIC) of clove extract. The analysis identified seventeen components in the clove extract, predominantly flavonoids and phenolic compounds. The antibacterial efficacy of the Syzygium aromaticum Myrtaceae extract against P. aeruginosa indicated its potential as a promising antibacterial agent capable of enhancing the effectiveness of existing medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.